Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338585 · ClinicalTrials.gov registry record · Phase 3
Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
A Phase 3 study, sponsored by ARCA Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00338585 is a Phase 3 study that was terminated before completion, run by ARCA Biopharma. The registered enrollment target is 300 participants.
The verdict
NCT00338585, a Phase 3 study, was terminated before completion, sponsored by ARCA Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
Interventions
- DRUG alfimeprase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338585
The ClinicalTrials.gov registry entry for NCT00338585 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alfimeprase is the first listed.
NCT00338585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338585 about?
NCT00338585 is a clinical study titled "Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery". The purpose of this study is to directly compare the safety and efficacy of intra-thrombus alfimeprase 0.3 mg/kg with placebo in acute peripheral arterial occlusion (PAO) as measured by a 30 day open vascular free surgery rate.
What is the current status of trial NCT00338585?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2006-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00338585?
The interventions under investigation include: alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00338585?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.